Trials / Unknown
UnknownNCT03757936
A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Anti-PD-1 Antibody (HLX10) in Combination With Avastin Biosimilar (HLX04) in Patients With Advanced Solid Tumors
A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection (HLX10) in Combination With Recombinant Anti-VEGF Humanized Monoclonal Antibody Injection (HLX04) in Patients With Advanced Solid Tumors
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Shanghai Henlius Biotech · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-center, open-label, dose-escalation Phase I clinical trial to evaluate the safety and the tolerability of HLX10-HLX04 combination therapy in patients with advanced solid tumors after failure of standard of care.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HLX04 | Recombinant Anti-VEGF Humanized Monoclonal Antibody Injection |
| DRUG | HLX10 | Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection |
Timeline
- Start date
- 2018-11-27
- Primary completion
- 2019-09-27
- Completion
- 2020-12-27
- First posted
- 2018-11-29
- Last updated
- 2019-05-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03757936. Inclusion in this directory is not an endorsement.